Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 216

Cited In for PubMed (Select 314668)

1.

Childhood leukaemia and lymphoma: African experience supports a role for environmental factors in leukaemogenesis.

Williams CK, Foroni L, Luzzatto L, Saliu I, Levine A, Greaves MF.

Ecancermedicalscience. 2014 Nov 6;8:478. doi: 10.3332/ecancer.2014.478. eCollection 2014.

2.

Gene-modified cells for stem cell transplantation and cancer therapy.

Brenner MK.

Hum Gene Ther. 2014 Jul;25(7):563-9. doi: 10.1089/hum.2014.2527. Review. No abstract available.

PMID:
25029600
3.

Immunotherapeutic strategies in autoimmune uveitis.

Papotto PH, Marengo EB, Sardinha LR, Goldberg AC, Rizzo LV.

Autoimmun Rev. 2014 Sep;13(9):909-16. doi: 10.1016/j.autrev.2014.05.003. Epub 2014 May 12. Review.

4.

Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity.

Rushworth D, Jena B, Olivares S, Maiti S, Briggs N, Somanchi S, Dai J, Lee D, Cooper LJ.

J Immunother. 2014 May;37(4):204-13. doi: 10.1097/CJI.0000000000000032.

5.

Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients.

Locke JE, Singer AL.

Hepat Med. 2011 May 13;3:53-62. doi: 10.2147/HMER.S13682. Review.

6.

CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.

Chatenoud L, Waldmann H.

Rev Diabet Stud. 2012 Winter;9(4):372-81. doi: 10.1900/RDS.2012.9.372. Epub 2012 Dec 28. Review.

7.

Toward a molecular understanding of adaptive immunity: a chronology - part II.

Smith KA.

Front Immunol. 2012 Nov 29;3:364. doi: 10.3389/fimmu.2012.00364. eCollection 2012.

8.

Generation and characterization of monospecific and bispecific hexavalent trimerbodies.

Blanco-Toribio A, Sainz-Pastor N, Álvarez-Cienfuegos A, Merino N, Cuesta ÁM, Sánchez-Martín D, Bonet J, Santos-Valle P, Sanz L, Oliva B, Blanco FJ, Álvarez-Vallina L.

MAbs. 2013 Jan-Feb;5(1):70-9. doi: 10.4161/mabs.22698. Epub 2012 Dec 5.

9.

Regulation of integrin affinity on cell surfaces.

Schürpf T, Springer TA.

EMBO J. 2011 Sep 23;30(23):4712-27. doi: 10.1038/emboj.2011.333.

10.

A new pathway of CD5 glycoprotein-mediated T cell inhibition dependent on inhibitory phosphorylation of Fyn kinase.

Bamberger M, Santos AM, Gonçalves CM, Oliveira MI, James JR, Moreira A, Lozano F, Davis SJ, Carmo AM.

J Biol Chem. 2011 Sep 2;286(35):30324-36. doi: 10.1074/jbc.M111.230102. Epub 2011 Jul 8.

11.

Humanizing animal models: a key to autoimmune diabetes treatment.

Bresson D, von Herrath M.

Sci Transl Med. 2011 Feb 2;3(68):68ps4. doi: 10.1126/scitranslmed.3002102.

12.

ORTHOCLONE OKT3 in Treatment of Allografts Rejected Under Cyclosporine-Steroid Therapy.

Starzl TE, Fung JJ.

Transplant Proc. 1986 Aug;18(4):937-941. No abstract available.

13.

Epigenetic quantification of tumor-infiltrating T-lymphocytes.

Sehouli J, Loddenkemper C, Cornu T, Schwachula T, Hoffmüller U, Grützkau A, Lohneis P, Dickhaus T, Gröne J, Kruschewski M, Mustea A, Turbachova I, Baron U, Olek S.

Epigenetics. 2011 Feb;6(2):236-46. Epub 2011 Feb 1.

14.

Autoimmune-associated PTPN22 R620W variation reduces phosphorylation of lymphoid phosphatase on an inhibitory tyrosine residue.

Fiorillo E, Orrú V, Stanford SM, Liu Y, Salek M, Rapini N, Schenone AD, Saccucci P, Delogu LG, Angelini F, Manca Bitti ML, Schmedt C, Chan AC, Acuto O, Bottini N.

J Biol Chem. 2010 Aug 20;285(34):26506-18. doi: 10.1074/jbc.M110.111104. Epub 2010 Jun 9.

15.

Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.

Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, Ng SB, Born T, Retter M, Manchulenko K, Sweet H, Foltz IN, Wittekind M, Yan W.

J Biol Chem. 2010 Jun 18;285(25):19637-46. doi: 10.1074/jbc.M110.117382. Epub 2010 Apr 16.

16.

A comprehensive review of immunosuppression used for liver transplantation.

Mukherjee S, Mukherjee U.

J Transplant. 2009;2009:701464. doi: 10.1155/2009/701464. Epub 2009 Jul 16.

17.

Teplizumab therapy for type 1 diabetes.

Masharani UB, Becker J.

Expert Opin Biol Ther. 2010 Mar;10(3):459-65. doi: 10.1517/14712591003598843. Review.

18.

Immunological dysfunction in HIV-1-infected individuals caused by impairment of adenosine deaminase-induced costimulation of T-cell activation.

Martinez-Navio JM, Climent N, Pacheco R, Garcia F, Plana M, Nomdedeu M, Oliva H, Rovira C, Miralles L, Gatell JM, Gallart T, Mallol J, Lluis C, Franco R.

Immunology. 2009 Nov;128(3):393-404. doi: 10.1111/j.1365-2567.2009.03121.x.

19.

Regulation of lymphoid tyrosine phosphatase activity: inhibition of the catalytic domain by the proximal interdomain.

Liu Y, Stanford SM, Jog SP, Fiorillo E, Orrú V, Comai L, Bottini N.

Biochemistry. 2009 Aug 11;48(31):7525-32. doi: 10.1021/bi900332f.

20.

A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus.

Orrú V, Tsai SJ, Rueda B, Fiorillo E, Stanford SM, Dasgupta J, Hartiala J, Zhao L, Ortego-Centeno N, D'Alfonso S; Italian Collaborative Group, Arnett FC, Wu H, Gonzalez-Gay MA, Tsao BP, Pons-Estel B, Alarcon-Riquelme ME, He Y, Zhang ZY, Allayee H, Chen XS, Martin J, Bottini N.

Hum Mol Genet. 2009 Feb 1;18(3):569-79. doi: 10.1093/hmg/ddn363. Epub 2008 Nov 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk